Vivet Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Vivet Therapeutics's estimated annual revenue is currently $5.7M per year.
- Vivet Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Vivet Therapeutics has 37 Employees.
- Vivet Therapeutics grew their employee count by -7% last year.
Vivet Therapeutics's People
Name | Title | Email/Phone |
---|
Vivet Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.6M | 81 | -5% | N/A | N/A |
#2 | $19.5M | 126 | -2% | N/A | N/A |
#3 | $36.3M | 234 | 22% | N/A | N/A |
#4 | $19.7M | 127 | -17% | N/A | N/A |
#5 | $14.3M | 92 | 0% | $179.5M | N/A |
#6 | $49.4M | 208 | -8% | €201.1M | N/A |
#7 | $44.5M | 287 | -3% | N/A | N/A |
#8 | $7.6M | 49 | N/A | N/A | N/A |
#9 | $6.4M | 41 | N/A | N/A | N/A |
#10 | $17.2M | 111 | -15% | N/A | N/A |
What Is Vivet Therapeutics?
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
keywords:N/AN/A
Total Funding
37
Number of Employees
$5.7M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vivet Therapeutics News
... including immune checkpoint inhibitors and cell therapies as well as ... General Counsel and Head of Finance at Vivet Therapeutics,...
Key Intrahepatic Cholangiocarcinoma pipeline therapies in various ... such as Mirum Pharmaceuticals, Vivet Therapeutics, among others.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.5M | 37 | -20% | N/A |
#2 | $4.3M | 37 | N/A | N/A |
#3 | $9M | 37 | 12% | N/A |
#4 | $6.9M | 37 | 12% | N/A |
#5 | $4.3M | 37 | 6% | N/A |